156 related articles for article (PubMed ID: 28102776)
1. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac.
Sudha T; Bharali DJ; Yalcin M; Darwish NH; Coskun MD; Keating KA; Lin HY; Davis PJ; Mousa SA
Nanomedicine (Lond); 2017 Feb; 12(3):195-205. PubMed ID: 28102776
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac.
Sudha T; Bharali DJ; Yalcin M; Darwish NH; Debreli Coskun M; Keating KA; Lin HY; Davis PJ; Mousa SA
Int J Nanomedicine; 2017; 12():1305-1315. PubMed ID: 28243091
[TBL] [Abstract][Full Text] [Related]
3. Nano Diaminopropane tetrac and integrin αvβ3 expression in different cancer types: Anti-cancer efficacy and Safety.
Godugu K; Sudha T; Davis PJ; Mousa SA
Cancer Treat Res Commun; 2021; 28():100395. PubMed ID: 34034044
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.
Sudha T; Bharali DJ; Sell S; Darwish NHE; Davis PJ; Mousa SA
Horm Cancer; 2017 Jun; 8(3):157-165. PubMed ID: 28396979
[TBL] [Abstract][Full Text] [Related]
5. The combination of tetraiodothyroacetic acid and cetuximab inhibits cell proliferation in colorectal cancers with different K-ras status.
Lee YS; Chin YT; Yang YSH; Wei PL; Wu HC; Shih A; Lu YT; Pedersen JZ; Incerpi S; Liu LF; Lin HY; Davis PJ
Steroids; 2016 Jul; 111():63-70. PubMed ID: 26980146
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle.
Li W; Yalcin M; Bharali DJ; Lin Q; Godugu K; Fujioka K; Keating KA; Mousa SA
Sci Rep; 2019 Jun; 9(1):9006. PubMed ID: 31227723
[TBL] [Abstract][Full Text] [Related]
7. Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Lin HY; Chin YT; Nana AW; Shih YJ; Lai HY; Tang HY; Leinung M; Mousa SA; Davis PJ
Steroids; 2016 Oct; 114():59-67. PubMed ID: 27221508
[TBL] [Abstract][Full Text] [Related]
8. Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers.
Nana AW; Wu SY; Yang YS; Chin YT; Cheng TM; Ho Y; Li WS; Liao YM; Chen YR; Shih YJ; Liu YR; Pedersen J; Incerpi S; Hercbergs A; Liu LF; Whang-Peng J; Davis PJ; Lin HY
Horm Cancer; 2018 Oct; 9(5):349-360. PubMed ID: 30027502
[TBL] [Abstract][Full Text] [Related]
9. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
10. Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.
Chang TC; Chin YT; Nana AW; Wang SH; Liao YM; Chen YR; Shih YJ; Changou CA; Yang YS; Wang K; Whang-Peng J; Wang LS; Stain SC; Shih A; Lin HY; Wu CH; Davis PJ
Horm Cancer; 2018 Dec; 9(6):420-432. PubMed ID: 30187356
[TBL] [Abstract][Full Text] [Related]
11. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor.
Lee S; Kim J; Shim G; Kim S; Han SE; Kim K; Kwon IC; Choi Y; Kim YB; Kim CW; Oh YK
J Control Release; 2012 Dec; 164(2):213-20. PubMed ID: 22664473
[TBL] [Abstract][Full Text] [Related]
12. Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac).
Leith JT; Hercbergs A; Kenney S; Mousa SA; Davis PJ
Endocr Res; 2018 Nov; 43(4):215-219. PubMed ID: 29611723
[TBL] [Abstract][Full Text] [Related]
13. Electrohydrodynamic fabrication of core-shell PLGA nanoparticles with controlled release of cisplatin for enhanced cancer treatment.
Reardon PJ; Parhizkar M; Harker AH; Browning RJ; Vassileva V; Stride E; Pedley RB; Edirisinghe M; Knowles JC
Int J Nanomedicine; 2017; 12():3913-3926. PubMed ID: 28579777
[TBL] [Abstract][Full Text] [Related]
14. Nano-Targeting of Thyrointegrin αvβ3 Receptor in Solid Tumors and Impact on Radiosensitization.
Sudha T; Rehman MU; Darwish NHE; Coskun MD; Satti JA; Davis PJ; Mousa SA
Radiat Res; 2021 Oct; 196(4):375-385. PubMed ID: 34260732
[TBL] [Abstract][Full Text] [Related]
15. Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
Lin SJ; Chin YT; Ho Y; Chou SY; Sh Yang YC; Nana AW; Su KW; Lim YT; Wang K; Lee SY; Shih YJ; Chen YR; Whang-Peng J; Davis PJ; Lin HY; Fu E
Food Chem Toxicol; 2018 Oct; 120():1-11. PubMed ID: 29960019
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
17. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid.
Yalcin M; Dyskin E; Lansing L; Bharali DJ; Mousa SS; Bridoux A; Hercbergs AH; Lin HY; Davis FB; Glinsky GV; Glinskii A; Ma J; Davis PJ; Mousa SA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1972-80. PubMed ID: 20133461
[TBL] [Abstract][Full Text] [Related]
18. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer.
Bharali DJ; Yalcin M; Davis PJ; Mousa SA
Nanomedicine (Lond); 2013 Dec; 8(12):1943-54. PubMed ID: 23448245
[TBL] [Abstract][Full Text] [Related]
19. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma.
Yalcin M; Bharali DJ; Dyskin E; Dier E; Lansing L; Mousa SS; Davis FB; Davis PJ; Mousa SA
Thyroid; 2010 Mar; 20(3):281-6. PubMed ID: 20187783
[TBL] [Abstract][Full Text] [Related]
20. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers With Different
Chin YT; He ZR; Chen CL; Chu HC; Ho Y; Su PY; Yang YSH; Wang K; Shih YJ; Chen YR; Pedersen JZ; Incerpi S; Nana AW; Tang HY; Lin HY; Mousa SA; Davis PJ; Whang-Peng J
Front Endocrinol (Lausanne); 2019; 10():130. PubMed ID: 30915033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
